Search Bar & Filters
Found 189 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of XYOSTED as a testosterone replacement therapy in adolescent males aged 12 to under 18 years with primary or secondary hypogonadism, a condition where the body produces little or no testosterone. This Phase 34 open-label study aims to assess how well XYOSTED supports the continuation or start of puberty, along with its safety and the testosterone levels it maintains. Participants will receive XYOSTED injections at doses tailored to their weight and targeted pubertal stage. Dose adjustments will be made based on testosterone levels measured at specific intervals after dosing, with evaluations approximately every three months to reach the desired hormone levels. After completing the 52-week initial study period, participants may enter a 24-month extension to further monitor long-term safety and treatment effects. Throughout the study and extension, participants will undergo clinical examinations including pubertal staging, blood tests for testosterone and other labs, bone density scans, body composition assessments, and X-rays to monitor bone age. Researchers will track changes in puberty progression, bone health, body measurements, and hormone levels. Participants will attend regular clinic visits every six months during the extension phase to continue safety and pharmacokinetic evaluations.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tenapanor in adults with Chronic Idiopathic Constipation CIC. This study is a 26-week, multi-center, randomized, double-blind, placebo-controlled trial followed by a 4-week treatment-free safety follow-up period. It aims to compare three different doses of tenapanor with a placebo taken twice daily to assess their impact on constipation symptoms. The study includes a 2-week screening period to confirm eligibility, followed by a 26-week randomized treatment period where patients receive either 5 mg, 25 mg, or 50 mg of tenapanor twice daily, or a matching placebo. Patients record their constipation symptoms daily in an electronic diary. After the treatment period, there is a 4-week safety follow-up without treatment to monitor any adverse effects. Participants will have regular visits every 2 to 6 weeks for safety checks including medical assessments, vital signs, ECG, and lab tests. Their symptom diaries will be reviewed throughout the study. The main outcome measured is the durable complete spontaneous bowel movements response at 12 weeks. Secondary outcomes include changes in bowel movement frequency, stool consistency, and straining. The total study duration is approximately 32 weeks including all phases.
Actively Recruiting
Researchers are evaluating remibrutinib, an oral medication, in a Phase III clinical trial involving adolescents and adults aged 12 to 65 with IgE-mediated allergies to peanut, cows milk cooked and uncooked, or hens egg cooked and uncooked. The study compares remibrutinib to a placebo to assess its safety and effectiveness in managing these food allergies. Participants are divided into four sub-studies based on their specific allergy peanut, milk, egg, or a combination of these allergens. During the initial treatment period, participants receive either remibrutinib or placebo for up to 24 weeks in the first three sub-studies, and up to 4 weeks in the fourth sub-study. After this, all participants enter an open-label phase where they receive remibrutinib until Week 52. Following this period, eligible participants can join a separate open-label post-trial study to evaluate long-term effects, while others enter a 4-week safety follow-up without treatment. Throughout the study, participants undergo regular assessments including allergen challenges to measure tolerance to specific amounts of allergen proteins at Weeks 4 and 24, depending on the sub-study. Safety is monitored by recording any adverse events up to 56 weeks. Participants are asked to avoid exposure to their allergens and complete skin prick tests, blood tests for allergen-specific IgE, and double-blind placebo-controlled food challenges. The trial duration is 52 weeks with additional follow-up for some participants.
Actively Recruiting
Researchers are evaluating a culturally-tailored home-based physical activity program designed for Hispanic or LatinoLatina adolescent and young adult childhood cancer survivors. These survivors may face long-term effects like weight gain, fatigue, and reduced physical fitness after cancer treatment. The study aims to see if this culturally-relevant program can help increase physical activity and improve overall health compared to using a Fitbit tracker alone. The study has two stages. In Stage 1, 20 Latinx survivors participate in developing the intervention using Fitbit trackers, text messages, social media support, wearable activity devices, and interviews over 9 months. In Stage 2, 170 survivors who do not meet physical activity guidelines are randomized to either the intervention group, which includes Fitbit use, weekly goal-setting, peer support via social media and Zoom meetings, and optional activity partners, or a control group that only uses Fitbit trackers for 12 weeks. The intervention includes an intensive phase with weekly sessions followed by a 4-week maintenance phase. Participants will wear Fitbit trackers daily and engage in goal-setting, peer discussions, and physical activity reminders. Researchers will measure moderate to vigorous physical activity, sedentary time, and health-related quality of life over 12 weeks. Additional evaluations include physiological markers of heart and metabolic health and qualitative interviews to improve the program. The study lasts through the intervention phases with ongoing monitoring and support for participants.
Actively Recruiting
Researchers are conducting a long-term extension study to evaluate the safety, tolerability, and effectiveness of ORX750 in adults aged 18 to 65 years who have narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. This study follows participants who completed a previous ORX750 clinical trial and focuses on providing ongoing information about the treatment over an extended period. Participants will receive oral ORX750 in an open-label format, grouped by their specific diagnosis narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. The study does not involve randomization or blinding, allowing all participants to know they are receiving the study drug. The treatment and monitoring periods include assessments up to about 70 days for safety and roughly 63 days for measures of drug concentration and wakefulness. During the study, participants will undergo frequent evaluations including monitoring for adverse events, laboratory tests, vital signs, ECGs, and assessments for suicidal thoughts or behaviors. They will also complete tests measuring wakefulness and sleepiness levels. This ongoing observation aims to ensure the treatments safety and to understand its effects over time, with participant involvement lasting through the entire study period.
Actively Recruiting
Researchers are investigating the long-term safety and effects of the medicine ritlecitinib in children with severe alopecia areata, a condition that causes significant hair loss. This Phase 3 study involves participants who have completed previous pediatric studies on ritlecitinib and aims to assess the drugs safety, tolerability, and effectiveness over an extended period. Participants will take ritlecitinib capsules by mouth once daily at home. Those who received different doses in prior studies will continue with the same dose or be randomly assigned to higher or lower doses in this trial. The study lasts up to 3 years, during which participants may be switched to placebo if they do not meet treatment continuation criteria. Throughout the study, participants will attend 17 clinic visits and receive monthly phone calls for monitoring. Researchers will evaluate safety by tracking side effects and serious adverse events. Effectiveness will be measured using tools like the Severity of Alopecia Tool SALT scores, eyebrow and eyelash assessments, and various patient-reported outcomes. Assessments will occur regularly to observe changes and impacts on quality of life.
Actively Recruiting
Researchers are studying LTI-03, an experimental inhaled medication, for the treatment of Idiopathic Pulmonary Fibrosis IPF, a progressive and fatal lung disease that causes scarring and loss of lung function. The study aims to assess the safety, side effects, and potential benefits of LTI-03 in improving lung scarring and symptoms in patients diagnosed with IPF within the last five years. Participants on stable doses of certain approved IPF medications may join. The study is a Phase 2, randomized, double-blind, placebo-controlled trial comparing LTI-03 to a placebo. Participants will inhale LTI-03 or placebo capsules twice daily using a dry powder inhaler. The trial includes a 28-day screening period, a 24-week treatment period, and a 4-week follow-up. Lung scans will be done at the start and end of treatment, with several clinic visits throughout the study. Participants will attend up to nine clinic visits where lung function tests, blood samples for safety and disease markers, and questionnaires about IPF symptoms will be conducted. Safety will be monitored through physical exams, vital signs, heart tests, and tracking side effects and medication changes. The main outcome will measure safety by recording treatment-related side effects over 24 weeks, while lung function and lung scarring changes will also be evaluated.
Actively Recruiting
Researchers are evaluating the use of remibrutinib, a Brutons tyrosine kinase BTK inhibitor, in adults with moderate-to-severe papulopustular rosacea PPR. This Phase 2 study aims to determine if remibrutinib can reduce inflammatory lesions on the face while assessing its safety and tolerability in this condition. The study is randomized, double-blind, and placebo-controlled, involving multiple centers. After a screening period of up to 30 days, during which participants must stop certain rosacea treatments and systemic therapies, eligible adults are randomly assigned to receive either remibrutinib or a matching placebo. This treatment phase lasts 16 weeks, followed by a safety follow-up visit about 30 days after the last dose. Participants take the study drug orally. During the trial, participants undergo evaluations of their facial inflammatory lesions at the start and after 16 weeks of treatment. Researchers track changes in lesion counts and severity using an Investigators Global Assessment scale. Safety and tolerability are monitored throughout the study. Total participation includes screening, treatment, and follow-up lasting several months.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.
Actively Recruiting
Researchers are evaluating the safety, tolerability, and preliminary effectiveness of AMO959 combined with lutetium 177Lu vipivotide tetraxetan AAA617 and androgen receptor pathway inhibitors ARPIs in adult men with PSMA-positive metastatic castration resistant prostate cancer mCRPC. This study includes participants who have failed one prior ARPI treatment, with or without previous taxane chemotherapy exposure. The study has two phases Phase Ib focuses on safety and dosing, and Phase II evaluates preliminary efficacy. The study consists of two phases. Phase Ib includes three dose level groups assessing AMO959 alone first, then combined with AAA617 and ARPI abiraterone or enzalutamide. Dose escalation meetings determine the recommended dose for expansion. Phase II randomizes participants into three arms to receive AMO959 with AAA617 and ARPI, AAA617 with ARPI, or other combinations, with treatments given in cycles up to six times every six weeks. Participants will receive study drugs in scheduled cycles and undergo regular assessments including monitoring for dose-limiting toxicities, adverse events, dose adjustments, drug exposure, and biochemical responses such as PSA levels. Safety and treatment effects are tracked up to approximately 24 to 45 months. The study involves multiple visits for treatment and follow-up evaluations, measuring outcomes like progression-free survival, response rates, and quality of life.
1-10 of 189
1